Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
Bazziggr
Bazziggr Aug. 4 at 8:44 PM
$AZN $145?
1 · Reply
BreakoutTrends
BreakoutTrends Aug. 4 at 7:50 PM
$AZN gift
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 4 at 7:15 PM
$SLS This $12 Share Price will be $112 and MORE ... Watch . . . . Gps Immunotherapy for AML Remission Maintenance - Phase 3 Results Now Imminent. Standby for Top Line Results - Will be adding $20B to SLS Market Cap in an Instant. $2B Manipulated Equity about to be Worth Every nickel of $50B to Big Pharma. $AZN
0 · Reply
chartistmind
chartistmind Aug. 4 at 6:59 PM
$AZN i can’t find anything to buy in this market except this so starter. Also, bagholders, wtf happened here. Ah, nevermind.
0 · Reply
tymtested
tymtested Aug. 4 at 6:56 PM
$AZN HUGE buying opportunity with merger related drop already priced in.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 6:45 PM
AstraZeneca Faces Fresh Pressure As $400B Bristol Myers Deal Talks Reportedly Persist $AZN $BMY https://stocktwits.com/news/equity/markets/astra-zeneca-faces-fresh-pressure-as-400-b-bristol-myers-deal-talks-reportedly-persist/cZo5sQVRJ4h
0 · Reply
EmSol
EmSol Aug. 4 at 4:17 PM
$AZN wait the PR, saying we are not interested to merge
0 · Reply
EmSol
EmSol Aug. 4 at 4:14 PM
$AZN $225
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 3:23 PM
SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally? $SOPH $AZN https://stocktwits.com/news/equity/markets/soph-stock-heads-for-best-day-in-over-8-months-what-s-driving-today-s-super-rally/cZo5nzMRJEU
0 · Reply
Bazziggr
Bazziggr Aug. 4 at 11:17 AM
$AZN $140?
0 · Reply
Latest News on AZN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Tue, 04 Aug 2026 17:12:00 -0400 - 3 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

AstraZeneca deal talks with Bristol Myers remain active, Semafor says

2026-08-04T16:40:46.000Z - 8 hours ago

AstraZeneca deal talks with Bristol Myers remain active, Semafor says

BMY

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Tue, 04 Aug 2026 06:15:00 -0400 - 14 hours ago

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Tue, 04 Aug 2026 01:30:00 -0400 - 19 hours ago

More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued

2026-08-03T22:09:48.000Z - 1 day ago

Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued

Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers

2026-08-03T21:02:02.000Z - 1 day ago

Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers

Soriot plots pharma Brexit: Labour's failures have alienated a national champion, says ALEX BRUMMER

2026-08-03T21:01:43.000Z - 1 day ago

Soriot plots pharma Brexit: Labour's failures have alienated a national champion, says ALEX BRUMMER

AZN Looks 12.5% Undervalued on GF Value™ as Dividend Remains Secure

2026-08-03T19:50:42.000Z - 1 day ago

AZN Looks 12.5% Undervalued on GF Value™ as Dividend Remains Secure

European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops

2026-08-03T18:31:34.000Z - 1 day ago

European Stocks Rise as Oil Prices Fall Amid US-Iran Tensions, AstraZeneca Drops

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

2026-08-03T18:25:20.000Z - 1 day ago

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

BMY

FTSE 100 Slips as AstraZeneca Falls on Merger Reports

2026-08-03T18:14:57.000Z - 1 day ago

FTSE 100 Slips as AstraZeneca Falls on Merger Reports

AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks

2026-08-03T18:04:11.000Z - 1 day ago

AstraZeneca Shares Slide on $400bn Bristol Myers Merger Talks

AZN Looks 14.0% Undervalued on GF Value™ Amid Dividend Sustainability Concerns

2026-08-03T17:59:56.000Z - 1 day ago

AZN Looks 14.0% Undervalued on GF Value™ Amid Dividend Sustainability Concerns

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

2026-08-03T17:24:33.000Z - 1 day ago

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

2026-08-03T17:22:28.000Z - 1 day ago

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee

2026-08-03T17:12:55.000Z - 1 day ago

AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee

Stocks mixed as AstraZeneca merger talk dents FTSE 100

2026-08-03T16:14:13.000Z - 1 day ago

Stocks mixed as AstraZeneca merger talk dents FTSE 100

AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025

2026-08-03T16:12:33.000Z - 1 day ago

AstraZeneca (AZN) Faces Significant Drop, Hits Lowest Level Since 2025

Astra Buying Bristol Makes No Sense, Fazeli Says

Mon, 03 Aug 2026 11:38:58 -0400 - 1 day ago

Astra Buying Bristol Makes No Sense, Fazeli Says

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Mon, 03 Aug 2026 11:20:39 -0400 - 1 day ago

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

AZN Looks 5.6% Undervalued on GF Value™

2026-08-03T14:51:01.000Z - 1 day ago

AZN Looks 5.6% Undervalued on GF Value™

Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns

2026-08-03T14:11:29.000Z - 1 day ago

Potential Merger Between Bristol-Myers Squibb (BMY) and AstraZeneca Raises Concerns

AZN Looks 5.6% Undervalued on GF Value™ Amid Strong Dividend Fundamentals

2026-08-03T13:59:15.000Z - 1 day ago

AZN Looks 5.6% Undervalued on GF Value™ Amid Strong Dividend Fundamentals

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

Mon, 03 Aug 2026 09:55:38 -0400 - 1 day ago

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger

2026-08-03T13:54:17.000Z - 1 day ago

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) Explore Potential Merger

AstraZeneca (AZN) Stock Drops Amid Merger Talks with Bristol-Myers Squibb (BMY)

2026-08-03T13:51:37.000Z - 1 day ago

AstraZeneca (AZN) Stock Drops Amid Merger Talks with Bristol-Myers Squibb (BMY)

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

2026-08-03T13:27:23.000Z - 1 day ago

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

AstraZeneca Stock Nosedives On Mega-Merger Rumor

2026-08-03T13:14:31.000Z - 1 day ago

AstraZeneca Stock Nosedives On Mega-Merger Rumor

Video: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks

2026-08-03T13:05:44.000Z - 1 day ago

Video: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks

BMY CRCL INDV MAR SRAD SUPN

5 Things to Know Before the Stock Market Opens on Monday

Mon, 03 Aug 2026 08:10:53 -0400 - 1 day ago

5 Things to Know Before the Stock Market Opens on Monday

AstraZeneca merging with Bristol Myers would be a big cost-cutting deal: Mizuho's Jared Holz

2026-08-03T12:00:37.000Z - 1 day ago

AstraZeneca merging with Bristol Myers would be a big cost-cutting deal: Mizuho's Jared Holz

Stocks making the biggest moves premarket: Alibaba, AstraZeneca, eBay & more

2026-08-03T11:35:57.000Z - 1 day ago

Stocks making the biggest moves premarket: Alibaba, AstraZeneca, eBay & more

AstraZeneca (AZN) Discusses Major Merger with Bristol-Myers Squibb

2026-08-03T11:10:38.000Z - 1 day ago

AstraZeneca (AZN) Discusses Major Merger with Bristol-Myers Squibb

Citi views report of AstraZeneca, Bristol Myers talks as surprising

2026-08-03T11:00:38.000Z - 1 day ago

Citi views report of AstraZeneca, Bristol Myers talks as surprising

BMY

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

Mon, 03 Aug 2026 06:43:00 -0400 - 1 day ago

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

AZN Looks 5.6% Undervalued on GF Value™ Amid Dividend Sustainability

2026-08-03T10:27:43.000Z - 1 day ago

AZN Looks 5.6% Undervalued on GF Value™ Amid Dividend Sustainability

AstraZeneca holds talks with US cancer drug developer in $400bn merger

Mon, 03 Aug 2026 06:22:41 -0400 - 1 day ago

AstraZeneca holds talks with US cancer drug developer in $400bn merger

AZN Looks 5.6% Undervalued on GF Value™ Amid Solid Dividend Fundamentals

2026-08-03T09:59:31.000Z - 1 day ago

AZN Looks 5.6% Undervalued on GF Value™ Amid Solid Dividend Fundamentals

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

Mon, 03 Aug 2026 05:54:00 -0400 - 1 day ago

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

AstraZeneca US M&A idea would ail more than cure

2026-08-03T09:49:16.785Z - 1 day ago

AstraZeneca US M&A idea would ail more than cure

FTSE 100 slips as AstraZeneca drops on Bristol Myers merger talks

2026-08-03T09:43:09.475Z - 1 day ago

FTSE 100 slips as AstraZeneca drops on Bristol Myers merger talks

AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb

2026-08-03T09:32:29.000Z - 1 day ago

AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

2026-08-03T09:18:40.000Z - 1 day ago

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger

2026-08-03T09:12:21.000Z - 1 day ago

AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger

AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks

2026-08-03T09:05:26.000Z - 1 day ago

AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks

BMY

Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks

2026-08-03T09:05:17.000Z - 1 day ago

Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks

BMY

AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker

2026-08-03T09:04:00.000Z - 1 day ago

AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker

Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?

Mon, 03 Aug 2026 04:46:33 -0400 - 1 day ago

Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks

Mon, 03 Aug 2026 04:06:00 -0400 - 1 day ago

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

Mon, 03 Aug 2026 03:52:36 -0400 - 1 day ago

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca shares tumble 7% after reported Bristol Myers talks

Aug 3, 2026, 3:20 AM EDT - 1 day ago

AstraZeneca shares tumble 7% after reported Bristol Myers talks

BMY

AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal

2026-08-03T06:21:59.000Z - 1 day ago

AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal

BMY

AstraZeneca in discussions to combine with Bristol Myers for $400B, FT says

2026-08-03T00:20:11.000Z - 2 days ago

AstraZeneca in discussions to combine with Bristol Myers for $400B, FT says

BMY

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

Aug 2, 2026, 5:40 PM EDT - 2 days ago

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

BMY

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Aug 2, 2026, 4:00 PM EDT - 2 days ago

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

BMY

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

Aug 2, 2026, 3:36 PM EDT - 2 days ago

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

BMY

AstraZeneca, Daiichi Sankyo’s Datroway approved in EU

2026-07-31T10:50:57.000Z - 4 days ago

AstraZeneca, Daiichi Sankyo’s Datroway approved in EU

A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors

Jul 31, 2026, 3:16 AM EDT - 4 days ago

A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors

ARGX CNQ NWG TECK

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

2026-07-27T14:15:25.000Z - 8 days ago

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

OMER

Omeros up 11% to $10.89 after AstraZeneca study failure

2026-07-27T14:15:17.000Z - 8 days ago

Omeros up 11% to $10.89 after AstraZeneca study failure

OMER

AstraZeneca drug prices evolving in response to Trump policy, executive says

Jul 27, 2026, 8:53 AM EDT - 8 days ago

AstraZeneca drug prices evolving in response to Trump policy, executive says

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed'

Jul 27, 2026, 8:09 AM EDT - 8 days ago

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed'

AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint

2026-07-27T11:16:00.000Z - 8 days ago

AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint

AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint

2026-07-27T11:00:27.000Z - 8 days ago

AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint

AstraZeneca reports Sone-Ve improved survival in gastric cancers

2026-07-27T11:00:10.000Z - 8 days ago

AstraZeneca reports Sone-Ve improved survival in gastric cancers

AstraZeneca Earnings Call Transcript: Q2 2026

Jul 27, 2026, 6:45 AM EDT - 8 days ago

AstraZeneca Earnings Call Transcript: Q2 2026

AstraZeneca Quarterly report: Q2 2026

Jul 27, 2026, 6:45 AM EDT - 8 days ago

AstraZeneca Quarterly report: Q2 2026

AstraZeneca Slides: Q2 2026

Jul 27, 2026, 6:45 AM EDT - 8 days ago

AstraZeneca Slides: Q2 2026

AstraZeneca reaffirms FY26 revenue, core EPS guidance

2026-07-27T10:11:19.000Z - 8 days ago

AstraZeneca reaffirms FY26 revenue, core EPS guidance

AstraZeneca's rare disease drug misses main goal in late-stage trial

Jul 27, 2026, 3:01 AM EDT - 8 days ago

AstraZeneca's rare disease drug misses main goal in late-stage trial

AstraZeneca Posts Sales Growth on Oncology Strength

Jul 27, 2026, 2:52 AM EDT - 8 days ago

AstraZeneca Posts Sales Growth on Oncology Strength

AstraZeneca beats second-quarter profit expectations, holds outlook

Jul 27, 2026, 2:04 AM EDT - 8 days ago

AstraZeneca beats second-quarter profit expectations, holds outlook

AstraZeneca 'magic' faces rare test after trial failure, share slide

Jul 24, 2026, 2:16 AM EDT - 11 days ago

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

Jul 23, 2026, 2:58 AM EDT - 12 days ago

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

Hair loss with GLP-1 drugs is rare, but real, studies find

Jul 22, 2026, 6:31 PM EDT - 13 days ago

Hair loss with GLP-1 drugs is rare, but real, studies find

LLY NVO

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

Jul 14, 2026, 2:55 AM EDT - 21 days ago

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Jul 14, 2026, 2:19 AM EDT - 21 days ago

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Jul 11, 2026, 1:00 AM EDT - 24 days ago

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca

Jul 10, 2026, 9:00 AM EDT - 25 days ago

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca

UK stocks decline as AstraZeneca tumbles after trial setback

Jul 9, 2026, 8:12 AM EDT - 26 days ago

UK stocks decline as AstraZeneca tumbles after trial setback

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

Jul 9, 2026, 7:38 AM EDT - 26 days ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

ALNY IONS

Major drugmaker loses $27 billion in market value after failed trial

Jul 9, 2026, 5:53 AM EDT - 26 days ago

Major drugmaker loses $27 billion in market value after failed trial

IONS

AstraZeneca shares plunge as Wainua fails late-stage heart disease trial

Jul 9, 2026, 4:49 AM EDT - 26 days ago

AstraZeneca shares plunge as Wainua fails late-stage heart disease trial

AstraZeneca stock dives 9% after heart drug trial misses target

Jul 9, 2026, 3:34 AM EDT - 26 days ago

AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca Says Wainua Trial Failed to Meet Primary Goal

Jul 9, 2026, 2:59 AM EDT - 26 days ago

AstraZeneca Says Wainua Trial Failed to Meet Primary Goal

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

Jul 9, 2026, 2:12 AM EDT - 26 days ago

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

IONS

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

Jul 8, 2026, 8:53 AM EDT - 27 days ago

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

Jul 7, 2026, 11:44 PM EDT - 27 days ago

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

Jul 7, 2026, 6:48 PM EDT - 4 weeks ago

Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

AstraZeneca Transcript: Investor update

Jul 6, 2026, 9:30 AM EDT - 4 weeks ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jul 6, 2026, 9:30 AM EDT - 4 weeks ago

AstraZeneca Slides: Investor update

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Jul 2, 2026, 6:16 AM EDT - 4 weeks ago

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Jul 1, 2026, 9:00 PM EDT - 4 weeks ago

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

Jun 24, 2026, 3:42 PM EDT - 5 weeks ago

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

GILD

Bazziggr
Bazziggr Aug. 4 at 8:44 PM
$AZN $145?
1 · Reply
BreakoutTrends
BreakoutTrends Aug. 4 at 7:50 PM
$AZN gift
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 4 at 7:15 PM
$SLS This $12 Share Price will be $112 and MORE ... Watch . . . . Gps Immunotherapy for AML Remission Maintenance - Phase 3 Results Now Imminent. Standby for Top Line Results - Will be adding $20B to SLS Market Cap in an Instant. $2B Manipulated Equity about to be Worth Every nickel of $50B to Big Pharma. $AZN
0 · Reply
chartistmind
chartistmind Aug. 4 at 6:59 PM
$AZN i can’t find anything to buy in this market except this so starter. Also, bagholders, wtf happened here. Ah, nevermind.
0 · Reply
tymtested
tymtested Aug. 4 at 6:56 PM
$AZN HUGE buying opportunity with merger related drop already priced in.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 6:45 PM
AstraZeneca Faces Fresh Pressure As $400B Bristol Myers Deal Talks Reportedly Persist $AZN $BMY https://stocktwits.com/news/equity/markets/astra-zeneca-faces-fresh-pressure-as-400-b-bristol-myers-deal-talks-reportedly-persist/cZo5sQVRJ4h
0 · Reply
EmSol
EmSol Aug. 4 at 4:17 PM
$AZN wait the PR, saying we are not interested to merge
0 · Reply
EmSol
EmSol Aug. 4 at 4:14 PM
$AZN $225
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 3:23 PM
SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally? $SOPH $AZN https://stocktwits.com/news/equity/markets/soph-stock-heads-for-best-day-in-over-8-months-what-s-driving-today-s-super-rally/cZo5nzMRJEU
0 · Reply
Bazziggr
Bazziggr Aug. 4 at 11:17 AM
$AZN $140?
0 · Reply
BearLady
BearLady Aug. 4 at 3:54 AM
$AZN AstraZeneca is learning the hard way that being the acquirer in a $400 billion pharma merger is like volunteering to be the tooth in a knife fight — you absorb all the pain while everyone watches. The market shaved $24 billion off AZN's market cap on a triple whammy of merger panic, a Phase 3 oncology flop, and IRA pricing pressure, and the options crowd's laughably lopsided P/C ratio of 0.17 screams "degens betting on a dead-cat bounce." With the stock 14.5% below its 200-day MA and a dividend ex-date in four days, this isn't a dip to buy — it's a falling knife with a dividend attached.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 4 at 3:17 AM
$AZN $SLS @Olivia_Strickland just load as much $SLS as you can nutsack up… 10x +++ ROI this month. • P3 Results are Imminent. There are 100,000 AML patients currently in Remission who’ll immediately benefit from Gps, Immunotherapy for remission maintenance. This rigged $2B mcap will be $20B the instant the P3 results are announced.
0 · Reply
DataClown
DataClown Aug. 4 at 3:09 AM
$AZN didn’t crash because earnings were weak — it crashed because investors questioned the future. A potential $400B BMS merger, pipeline setbacks like Wainua’s Phase III failure, and pressure behind its $80B 2030 revenue target are forcing the market to rethink AstraZeneca’s growth premium.
0 · Reply
topstockalerts
topstockalerts Aug. 4 at 2:31 AM
AstraZeneca has reportedly been in advanced discussions to merge with Bristol Myers Squibb in a transaction that could create one of the world's largest pharmaceutical companies, with a combined market value approaching $400 billion, according to the Financial Times. The companies have held talks for several months, although negotiations remain ongoing and the deal could still be delayed or ultimately collapse. AstraZeneca declined to comment, while Bristol Myers has not responded publicly. A tie-up would significantly strengthen the combined company's global presence in oncology, cardiovascular disease, immunology, and rare diseases, creating a broader pipeline and expanding its competitive position against other pharmaceutical giants. The report comes as AstraZeneca continues to deliver strong financial performance, driven by robust demand for its cancer and rare disease treatments. $AZN
0 · Reply
DgayukLEX13
DgayukLEX13 Aug. 4 at 2:19 AM
$AZN buy baby buy
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 1:46 AM
Why Did AMZN, SNOW, BMY Stocks Surge To 52-Week Highs Today? $ $AMZN $SNOW $BMY $AZN https://stocktwits.com/news/equity/markets/why-did-amzn-snow-bmy-stocks-surge-to-52-week-highs-today/cZo5c3GRJ3V
0 · Reply
freddycan
freddycan Aug. 3 at 9:50 PM
$AZN going back to 130
1 · Reply
jrh34
jrh34 Aug. 3 at 8:53 PM
$CRDF This could be related to speculation about $AZN and $BMY talking about mega-merger to create a $100B oncology powerhouse which could force $PFE into biotech M&A activity. Anyone that $PFE had previously had under IGNITE (Cardiff) could in theory be a takeout target. Any concerns around NMS legal issues become a moot point since $PFE in house counsel would bury and bankrupt NMS.
0 · Reply
leotardo
leotardo Aug. 3 at 8:04 PM
$AZN $160+ easily tomorrow
1 · Reply
green_going_up
green_going_up Aug. 3 at 7:47 PM
$AZN $BMY - With hundreds of biotech firms available to purchase, these firm's are discussing a merger. Not a fan of these cost-cutting synergy deals, when there are so many assets & platforms to acquire, integrate, and get approval.
0 · Reply
drdr3
drdr3 Aug. 3 at 7:18 PM
$AZN $BMY $MCRB something is happening here today folks. Low volume but this still looks to be the reversal we’ve been waiting 2+ years for.
0 · Reply
Quantumup
Quantumup Aug. 3 at 6:56 PM
TD Cowen doesn't see logic in a combination of $AZN and $BMY. If combined, AZN's '27-'32 sales growth would be diluted by two percentage points, although EPS growth would be boosted by two percentage points. Should a combination take place, it could make for a good stock in the near term, driven by synergies, but a less compelling company over the long-term, as precedent has shown. Overall, TD Cowen thinks AZN is one of the stronger companies in pharma today, so there isn't a compelling need to merge, particularly given the disruption that results, while BMY faces considerable challenges, with very large patent risk.
0 · Reply